close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

748.71 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
58 59 Next >
News headline image
Could This Biosimilar Drug Be Novartis' Next Blockbuster? ↗
Novartis expects to submit regulatory applications for its biosimilar soon. 
Via The Motley Fool
News headline image
Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing? ↗
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN) 
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With REGN ↗
 
Via Benzinga
News headline image
Is Regeneron Stock a Buy Now? ↗
The company's growth fuel isn't running out yet. 
Via The Motley Fool
News headline image
Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy ↗
Celularity Inc (NASDAQ: CELU) shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN). 
Via Benzinga
News headline image
Wall Street Thinks This Tiny Biotech Company Could Soar Soon ↗
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle. 
Via The Motley Fool
News headline image
These Are the ONLY 7 Penny Stocks to Consider in August 2023 ↗
These are just a few of the most promising penny stocks to consider as we head into the final months of the year. 
Via InvestorPlace
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Could This Medicine Be the Next Winner for Novartis? ↗
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials. 
Via The Motley Fool
News headline image
18 Analysts Have This to Say About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Fall Off A Cliff ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was awarded a government contract valued at up to $326 million on Tuesday. 
Via Benzinga
News headline image
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapy 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition? ↗
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,  
Via Benzinga
News headline image
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed ↗
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies... 
Via Benzinga
Topics ETFs
News headline image
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner ↗
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
News headline image
FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder ↗
The FDA approved  Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient  
Via Benzinga
News headline image
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms ↗
The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected. 
Via Investor's Business Daily
News headline image
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness ↗
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
News headline image
Is Regeneron Pharmaceuticals Still a Top Growth Stock? ↗
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
News headline image
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica (Nasdaq - SOLO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today